Emerging Agents for T790M-Mutant Patients With NSCLC

T-DM1 was tolerable in HER2-positive biliary tract adenocarcinoma but did not significantly improve progression-free survival.

In this episode, Joshua K. Sabari, MD, discusses the FDA approval of amivantamab plus chemotherapy as a first-line treatment for patients with EGFR exon 20 insertion mutation-positive non-small cell lung cancer.

Patients with BRAF V600E-mutant metastatic colorectal cancer experienced poor clinical outcomes with systemic therapy, according to real-world data.

In this episode of Targeted Talks, Aaron Lisberg, MD, discusses results from the phase 3 TROPION-Lung01 study of datopotamab in advanced or metastatic non–small cell lung cancer.

Early palliative care reduces invasive interventions and enhances comfort at EOL for CRC patients, according to real-world study results.

The phase 2b REZILIENT1 trial of zipalertinib in EGFR+ non–small cell lung cancer met its overall response rate primary end point with a consistent safety profile.